EyePoint Pharmaceuticals, Inc. (PV3B.F)
| Previous Close | 10.02 |
| Open | 9.74 |
| Bid | 9.66 x N/A |
| Ask | 10.05 x N/A |
| Day's Range | 9.69 - 9.74 |
| 52 Week Range | 5.25 - 28.60 |
| Volume | |
| Avg. Volume | 27 |
| Market Cap | 515.017M |
| Beta (5Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.67 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.20 |
Simply Wall St.Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gain
The last three months have been tough on EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders, who have seen the...
GuruFocus.comInsider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
On May 14, 2024, David Guyer, Director at EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a sale of 11,625 shares of the company.
GlobeNewswireEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an a
